艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

盘后交易 01-08 19:18:37 EST

69.69

-0.35

-0.50%

盘后69.23

-0.46-0.66%

18:40 EST

最高70.14	最低69.16	成交量81.38万
今开69.82	昨收70.04	日振幅1.40%
总市值75.96亿	流通市值74.57亿	总股本1.09亿
成交额5,669万	换手率0.76%	流通股本1.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":69.69,"timestamp":1736370000000,"preClose":70.04,"halted":0,"volume":813848,"hourTrading":{"tag":"盘后","latestPrice":69.23,"preClose":69.69,"latestTime":"18:40 EST","volume":50149,"amount":3494875.28467,"timestamp":1736379625193},"delay":0,"floatShares":107000000,"shares":109000000,"eps":1.809026,"marketStatus":"盘后交易","change":-0.35,"latestTime":"01-08 19:18:37 EST","open":69.82,"high":70.14,"low":69.16,"amount":56693945.69832,"amplitude":0.013992,"askPrice":69.91,"askSize":99,"bidPrice":69.12,"bidSize":99,"shortable":3,"etf":0,"ttmEps":1.809026,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1736384400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":70.04,"dividendRate":0.042789,"preHourTrading":{"tag":"盘前","latestPrice":70.04,"preClose":70.04,"latestTime":"08:49 EST","volume":4808,"amount":336752.252688,"timestamp":1736344172669},"postHourTrading":{"tag":"盘后","latestPrice":69.23,"preClose":69.69,"latestTime":"18:40 EST","volume":50149,"amount":3494875.28467,"timestamp":1736379625193},"volumeRatio":0.641905,"impliedVol":0.1982,"impliedVolPercentile":0.3452},"requestUrl":"/m/hq/s/ADC/wiki","defaultTab":"wiki","newsList":[{"id":"2502802620","title":"君实生物双抗ADC获批临床；默沙东K药联合疗法获批新适应症 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2502802620","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502802620?lang=zh_cn&edition=full","pubTime":"2025-01-09 07:45","pubTimestamp":1736379910,"startTime":"0","endTime":"0","summary":"丨2025年1月9日星期四丨NO.1君实生物注射用JS212临床试验申请获受理1月8日，君实生物发布公告，称公司收到国家药品监督管理局核准签发的《受理通知书》，注射用JS212（项目代号“JS212”）的临床试验申请获得受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501093291765269.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501093291765269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001176.SGD","IE0002141913.USD","LU2361045086.USD","BK4080","BK1574","ADC","SG9999001440.SGD","IE00B1BXHZ80.USD","LU0238689110.USD","LU1093756325.SGD","LU0122379950.USD","LU0203345920.USD","LU1057294990.SGD","BK4534","LU1989772923.USD","LU2324357040.USD","IE00BLSP4452.SGD","LU0234572021.USD","BK4559","BK4516","LU1989771016.USD","LU2112291526.USD","MRK","LU2023250843.SGD","LU1066051811.HKD","LU1699723380.USD","LU2361044949.HKD","01877","IE00BJT1NW94.SGD","LU2106854487.HKD","LU2023250504.SGD","SG9999014575.USD","09939","LU1291159041.SGD","LU0985320562.USD","LU1941712264.USD","LU1023059063.AUD","LU0006306889.USD","IE00B2B36J28.USD","LU1116320901.HKD","BK1161","LU0208291251.USD","LU0203347892.USD","BK4007","SG9999014567.USD","LU2461242641.AUD","IE00BN8TJ469.HKD","LU0265550359.USD","SG9999001176.USD","LU0266013472.USD"],"gpt_icon":0},{"id":"2502708710","title":"Nuvation Bio Inc.盘中异动 大幅下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502708710","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502708710?lang=zh_cn&edition=full","pubTime":"2025-01-09 01:02","pubTimestamp":1736355763,"startTime":"0","endTime":"0","summary":"北京时间2025年01月09日01时02分，Nuvation Bio Inc.股票出现波动，股价快速下挫5.08%。截至发稿，该股报3.09美元/股，成交量101.121万股，换手率0.30%，振幅7.08%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010901024395fd1891&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010901024395fd1891&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC","NUVB","BK4231","BK4080","DDC","BK4007","BK4212"],"gpt_icon":0},{"id":"2501771230","title":"江海证券：DLL3药物研发热情升温 国产ADC药物前景广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2501771230","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501771230?lang=zh_cn&edition=full","pubTime":"2025-01-08 16:07","pubTimestamp":1736323662,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，江海证券发布研报称，随着国家对创新药研发的支持力度不断加大，以及肿瘤患者对新型治疗手段的迫切需求，DLL3靶点药物的研发将迎来更加广阔的市场空间。建议关注在DLL3靶点药物研发领域具有领先地位的国内药企和拥有先进ADC 药物研发平台的公司。事件：近年来，DLL3作为肿瘤治疗领域备受瞩目的靶点，其药物研发热情持续升温。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU2328871848.SGD","BK1574","ADC","BK4231","161027","09688","BK1589","BK1161","01801","BK1588","LU1969619763.USD","LU2488822045.USD","BK4080"],"gpt_icon":0},{"id":"2501795539","title":"A股科创板公司“迈威生物-B”递表港交所，2024前十个月亏损8.6亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2501795539","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501795539?lang=zh_cn&edition=full","pubTime":"2025-01-08 11:04","pubTimestamp":1736305445,"startTime":"0","endTime":"0","summary":"迈威生物于2025年1月6日向港交所递交招股书，拟在香港主板上市，这是公司第1次递交上市申请，联席保荐人为中信证券和海通国际，公司是A股上市的中国领先的生物制药公司。2023年收入1.28亿元，净亏损10.6亿元，2024年前10个月收入1.6亿，净亏损8.6亿，研发开支占比70.18%。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202501_1/e80d4b8a-5132-44c1-b37b-62416037d56e.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202501_1/e80d4b8a-5132-44c1-b37b-62416037d56e.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/677deb252308291263de7de9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"2501782123","title":"割爱“现金奶牛”上海和黄45%股权 和黄药业：抗体靶向偶联药物需更多资金支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2501782123","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501782123?lang=zh_cn&edition=full","pubTime":"2025-01-08 00:35","pubTimestamp":1736267711,"startTime":"0","endTime":"0","summary":"1月1日，和黄医药（中国）有限公司（以下简称“和黄医药”）公告称，拟以6.08亿美元出售上海和黄药业有限公司（以下简称“上海和黄”）45%的股权。公开数据显示，上海和黄的主要产品为麝香保心丸，过去二十年，上海和黄累计为和黄医药带来逾3.7亿美元的股息，堪称“现金奶牛”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501083290230835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK1588","BK4080","BK4231","BK1191","00013","BK1587"],"gpt_icon":0},{"id":"2501200853","title":"Nuvation Bio Inc.盘中异动 快速拉升5.63%报3.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501200853","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501200853?lang=zh_cn&edition=full","pubTime":"2025-01-07 22:30","pubTimestamp":1736260225,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日22时30分，Nuvation Bio Inc.股票出现波动，股价急速拉升5.63%。截至发稿，该股报3.00美元/股，成交量5.4613万股，换手率0.02%，振幅0.00%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223026985e12a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223026985e12a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4563","BK4212","BK4007","IMRX","BK4080","BK4139","DDC","BK4231","ADC","NUVB"],"gpt_icon":0},{"id":"2501041742","title":"南北船千亿合并案获批！“一代鞋王”跨界收购告吹 | 盘后公告精选","url":"https://stock-news.laohu8.com/highlight/detail?id=2501041742","media":"金十数据","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501041742?lang=zh_cn&edition=full","pubTime":"2025-01-07 21:25","pubTimestamp":1736256319,"startTime":"0","endTime":"0","summary":"“中船系”两大千亿级主角合并更进一步，四连板大农业概念热股提示风险，没落“鞋王”转型梦碎......","market":"hk","thumbnail":"https://img.jin10.com/news/24/12/1Ix0B6iUNZJpFbqmQUZrV.jpg/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/news/24/12/1Ix0B6iUNZJpFbqmQUZrV.jpg/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=158264&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["BK4231","BK4017","ADC","BK4080","CDE"],"gpt_icon":0},{"id":"2501747882","title":"科伦药业：子公司核心产品博度曲妥珠单抗的新药申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2501747882","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501747882?lang=zh_cn&edition=full","pubTime":"2025-01-07 19:26","pubTimestamp":1736249212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2148510915.USD","399441","159992","06978","BK7050","BK1574","161726","LU1064131003.USD","BK4231","002422","BK0239","BK4017","BK1161","CDE.AU","BK7095","LU1064130708.USD","BK4080","ADC","ADC.AU","BK0060","CDE"],"gpt_icon":0},{"id":"2501274332","title":"【科伦药业：子公司博度曲妥珠单抗新药申请获国家药监局受理】金融界1月7日消息，科伦药业近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司的博度曲妥珠单抗的新药申请已获中国国家药品监督管理局药品审评中心受理，用于既往至少接受过一种抗 HER2 治疗的 HER2 阳性不可切除或转移性乳腺癌成人患者的治疗。该申请是基于一项多中心、随机、开放、对照、III 期临床研究。博度曲妥珠单抗是公司研发的创新 HER2 ADC，其通过特定机制发挥作用。创新药物研发具有不确定性，公司将根据后续进展及时履行信息披露义务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501274332","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501274332?lang=zh_cn&edition=full","pubTime":"2025-01-07 19:16","pubTimestamp":1736248565,"startTime":"0","endTime":"0","summary":"金融界1月7日消息，科伦药业近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司的博度曲妥珠单抗的新药申请已获中国国家药品监督管理局药品审评中心受理，用于既往至少接受过一种抗 HER2 治疗的 HER2 阳性不可切除或转移性乳腺癌成人患者的治疗。该申请是基于一项多中心、随机、开放、对照、III 期临床研究。博度曲妥珠单抗是公司研发的创新 HER2 ADC，其通过特定机制发挥作用。创新药物研发具有不确定性，公司将根据后续进展及时履行信息披露义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/07191647218908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","LU1064130708.USD","399441","LU2148510915.USD","ADC","III","002422","BK0060","06978","161726","LU1064131003.USD","159992","BK1574","BK4080","BK4134","BK1161","BK4231"],"gpt_icon":0},{"id":"2501229387","title":"21私募投融资周报（12.30-1.5）：长安凯程获得20亿元A轮融资，拿森科技完成5亿元D轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2501229387","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501229387?lang=zh_cn&edition=full","pubTime":"2025-01-07 15:43","pubTimestamp":1736235781,"startTime":"0","endTime":"0","summary":"新的一周开始，简单回顾上周披露的投融资交易。消费服务领域新披露融资中，餐饮和运输共完成2笔融资，服饰和物流各完成1笔融资。其中规模较大的是沃兰特航空完成数亿元Pre-B轮融资，由建发新兴投资、元璟资本、千乘资本、张科垚坤基金、中国互联网投资基金等投资。医疗健康领域新披露融资中，其中创新药完成3笔融资，合成生物学和医疗器械各完成2笔和1笔融资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501073289863959.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501073289863959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4231","BK4588","BK4023","IOT","BK4080","BK4585"],"gpt_icon":0},{"id":"2501290057","title":"【湾区早参】广州数字人民币2.0方案出炉；2024年澳门航空货运同比增长近七成","url":"https://stock-news.laohu8.com/highlight/detail?id=2501290057","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501290057?lang=zh_cn&edition=full","pubTime":"2025-01-07 08:39","pubTimestamp":1736210347,"startTime":"0","endTime":"0","summary":"据统计，新年前夕的旅游高峰期，2024年12月单月机场客运量68万人次，飞机起降量5280架次，同比分别增加14%及9.6%。货运市场方面，2024年航空货运处理量达10.8万吨，同比增长近七成。","market":"other","thumbnail":"https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1950829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320","BK1240","BK1555","02005","BK1170","03708","01918","BK1148","BK1583","00732","02096","BK4080","BK1599","LU2460026573.USD","BK1521","BK1570","BK1191","ADC","BK4231"],"gpt_icon":0},{"id":"2501245720","title":"A股生物医药公司密集赴港，迈威生物递表港交所，2024前十个月收入1.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501245720","media":"独角兽早知道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501245720?lang=zh_cn&edition=full","pubTime":"2025-01-07 08:10","pubTimestamp":1736208600,"startTime":"0","endTime":"0","summary":"截至1月6日收盘，迈威生物报18.65元/股，市值74.53亿元。截至最后实际可行日期，迈威生物的研发团队由403名人员组成。于往绩记录期间，迈威生物的大部分药品销售收入来自中国的第三方分销商。截至2024年10月31日，公司的分销网络由107名分销商组成。财务数据方面，2022年、2023年及2024年前三季度，公司分别实现营业收入0.28亿元、1.28亿元、1.41亿元；归母净亏损分别为9.55亿元、10.53亿元、6.94亿元。迈威生物的收入由截至2023年10月31日止十","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU3MTY1MzExOQ==&mid=2247590098&idx=2&sn=df68ee1134aaf01b82c33ccebb8eb746&chksm=fdbaa2bc85e0c0625a9ddf2b35fc042c7d46a8abe5d7ded00826bba3d541b89a6b8742277be2&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2501326374","title":"瑞银：上调Agree Realty评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2501326374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501326374?lang=zh_cn&edition=full","pubTime":"2025-01-07 02:05","pubTimestamp":1736186714,"startTime":"0","endTime":"0","summary":"瑞银：上调Agree Realty(ADC.US)评级，由中性调整至买入评级,目标价由79.00美元调整至84.00美元。美国同意房地产公司(ADC.US)公司简介：Agree Realty Corporation作为一家完全整合的房地产投资信托公司运营，主要专注于向行业领先租户净出租的零售物业的所有权、收购、开发和管理。该公司主要从事收购、开发和管理零售房地产业务。其投资组合中的一些资产包括沃尔玛、7-11、Wawa、Gerber Collision等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107021527a217c59d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107021527a217c59d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC"],"gpt_icon":0},{"id":"2501268458","title":"瑞银：上调Agree Realty(ADC.US)评级，由中性调整至买入评级, 目标价由79.00美元调整至84.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501268458","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501268458?lang=zh_cn&edition=full","pubTime":"2025-01-07 01:52","pubTimestamp":1736185924,"startTime":"0","endTime":"0","summary":"瑞银：上调Agree Realty(ADC.US)评级，由中性调整至买入评级, 目标价由79.00美元调整至84.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/07015247186476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADC"],"gpt_icon":0},{"id":"2501472091","title":"高盛：信达生物授权罗氏DLL3 ADC 目标于近期建立完整的全球基础设施","url":"https://stock-news.laohu8.com/highlight/detail?id=2501472091","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501472091?lang=zh_cn&edition=full","pubTime":"2025-01-06 13:18","pubTimestamp":1736140680,"startTime":"0","endTime":"0","summary":"　　高盛发布研报称，信达生物以1.08亿美元的价格将一款新型DLL3靶向抗体药物偶联物IBI3009授权给罗氏，此次DLL3ADC交易是信达生物自2020年与礼来公司达成泰瑞沙合作以来的首笔重大全球授权交易。公司管理层早前提到，授权协议是近期灵活且直接的全球选择，目标在近期为公司建立完整的全球基础设施。从长远来看，信达生物的DLL3","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-01-06/doc-ineczhrz2558083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","BK1583","BK4585","IE0004086264.USD","ADC","IE00BFXG1179.USD","LU2237443465.HKD","BK4588","BK4550","LU0106831901.USD","BK4504","LU2237443895.HKD","LU1791807156.HKD","LU2237443382.USD","01801","BK4533","BK1589","LU2237443549.SGD","BK4552","LU2237443622.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE0034235188.USD","BK4516","LU2488822045.USD","LU1668664300.SGD","IE0002270589.USD","BK4080","LU2237438978.USD","BK1161","IE0004091025.USD","LU1969619763.USD","LU2237443978.SGD","IE00B19Z3581.USD","LU2328871848.SGD","BK4127"],"gpt_icon":0},{"id":"2501473952","title":"高盛：信达生物(01801)授权罗氏DLL3 ADC 目标于近期建立完整的全球基础设施","url":"https://stock-news.laohu8.com/highlight/detail?id=2501473952","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501473952?lang=zh_cn&edition=full","pubTime":"2025-01-06 11:10","pubTimestamp":1736133054,"startTime":"0","endTime":"0","summary":"公司管理层早前提到，授权协议是近期灵活且直接的全球选择，目标在近期为公司建立完整的全球基础设施。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/source/image/16865.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/source/image/16865.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1233632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00B19Z3581.USD","IE00BSNM7G36.USD","BK1583","LU2328871848.SGD","IE00B19Z3B42.SGD","LU1969619763.USD","BK4550","IE0002270589.USD","BK4127","BK4552","01801","LU2237443978.SGD","LU2488822045.USD","BK4231","IE0034235188.USD","LU0106831901.USD","BK4080","IE0004091025.USD","LU2237443622.USD","LU2237443465.HKD","LU2237443382.USD","BK4585","BK4516","LU2237443895.HKD","LU2237438978.USD","IE0004086264.USD","LU1668664300.SGD","LU1791807156.HKD","BK4533","ADC","BK1589","BK4504","IE00BFXG1179.USD","BK1161","BK4588","LU2237443549.SGD"],"gpt_icon":0},{"id":"2500663117","title":"Nuvation Bio Inc.盘中异动 大幅上涨5.02%报2.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500663117","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500663117?lang=zh_cn&edition=full","pubTime":"2025-01-03 23:10","pubTimestamp":1735917033,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日23时10分，Nuvation Bio Inc.股票出现波动，股价快速上涨5.02%。截至发稿，该股报2.72美元/股，成交量7.1152万股，换手率0.02%，振幅4.07%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010323103395f7d92f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010323103395f7d92f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","ADC","BK4231","NUVB","BK4007","BK4080","BK4212"],"gpt_icon":0},{"id":"2500394590","title":"附属公司易主上海医药，和黄医药逾44亿元剥离中药资产，加码ADC开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2500394590","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500394590?lang=zh_cn&edition=full","pubTime":"2025-01-02 17:59","pubTimestamp":1735811950,"startTime":"0","endTime":"0","summary":"上海和黄药业由上海医药全资子公司上药药材与和黄医药合资成立，双方各持股50%，是和黄医药非合并合资企业。公告显示，上海和黄药业2023年度及2024年1-9月实现净利润分别为6.63亿元及5.73亿元。近年来，和黄医药持续加码创新药管线的发展。截至2024年6月30日，和黄医药现金及现金等价物和短期投资合计为8.025亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501021759199858b9c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501021759199858b9c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","HCM","ADC","BK4231","BK4588","BK4531","BK4080","BK4007"],"gpt_icon":0},{"id":"2500797969","title":"超10亿美元，信达生物一款ADC药物授权给罗氏","url":"https://stock-news.laohu8.com/highlight/detail?id=2500797969","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500797969?lang=zh_cn&edition=full","pubTime":"2025-01-02 09:55","pubTimestamp":1735782900,"startTime":"0","endTime":"0","summary":"2025年1月2日早间，信达生物（01801.HK）宣布将一款新药IBI3009的全球独家权益授予罗氏。根据协议，信达生物授予罗氏IBI3009的全球开发、生产和商业化的独家权益。双方将共同负责该ADC（抗体偶联药物）候选药物的早期开发，后续临床开发将由罗氏负责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501023285112010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501023285112010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","LU2488822045.USD","BK1583","01801","BK4080","ADC","BK1161","BK1589","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2500095263","title":"【信达生物(01801.HK)与罗氏达成新一代DLL3 抗体偶联药物的全球独家许可协议】信达生物(01801.HK)公布，该公司及其全资附属公司(包括信达生物制药(苏州)有限公司、Fortvita Biologics (Singapore) Pte. Ltd.及福佑泰生物制药有限公司与F. Hoffmann-La Roche Ltd及 Hoffmann-La Roche Inc.(连同F. Hoffmann-La Roche Ltd统称为“罗氏”)达成全球独家合作与许可协议，据此，该集团授予罗氏开发、生产及商业化IBI3009(一款靶向DLL3的新一代抗体偶联药物(ADC)候选产品)的全球独家权益。IBI3009已在澳大利亚、中国和美国获得临床申请(IND)批准，并于2024年12月完成I期临床研究首例患者给药。此次合作旨在为晚期小细胞肺癌 (SCLC)患者提供全新的治疗选择。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500095263","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500095263?lang=zh_cn&edition=full","pubTime":"2025-01-02 07:28","pubTimestamp":1735774134,"startTime":"0","endTime":"0","summary":"信达生物公布，该公司及其全资附属公司(包括信达生物制药(苏州)有限公司、Fortvita Biologics (Singapore) Pte. Ltd.及福佑泰生物制药有限公司与F. Hoffmann-La Roche Ltd及 Hoffmann-La Roche Inc.(连同F. Hoffmann-La Roche Ltd统称为“罗氏”)达成全球独家合作与许可协议，据此，该集团授予罗氏开发、生产及商业化IBI3009(一款靶向DLL3的新一代抗体偶联药物(ADC)候选产品)的全球独家权益。此次合作旨在为晚期小细胞肺癌 患者提供全新的治疗选择。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/02072847022908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2328871848.SGD","01801","BK1191","LU2488822045.USD","BK1583","LU1969619763.USD","FOYO","BK4080","ADC","01477","BK1574","BK1161","BK1589","BK4231"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":-0.0626},{"period":"3month","weight":-0.05},{"period":"6month","weight":0.0985},{"period":"1year","weight":0.0994},{"period":"ytd","weight":-0.0058}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.548387,"avgChangeRate":-0.004943},{"month":2,"riseRate":0.433333,"avgChangeRate":-0.00204},{"month":3,"riseRate":0.566667,"avgChangeRate":0.014268},{"month":4,"riseRate":0.566667,"avgChangeRate":0.002707},{"month":5,"riseRate":0.516129,"avgChangeRate":0.017098},{"month":6,"riseRate":0.677419,"avgChangeRate":0.011409},{"month":7,"riseRate":0.677419,"avgChangeRate":0.024183},{"month":8,"riseRate":0.451613,"avgChangeRate":0.001804},{"month":9,"riseRate":0.483871,"avgChangeRate":-0.005771},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.001244},{"month":11,"riseRate":0.645161,"avgChangeRate":0.002723},{"month":12,"riseRate":0.483871,"avgChangeRate":0.011628}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}